BioSpace News Archive

RAPT Therapeutics, Inc. reported financial results for the second quarter and the six months ended June 30, 2023.

Bionano Genomics, Inc. announced its participation at the Cancer Genomics Consortium 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping for solid tumor and hematological malignancy cancer research, including scientific platform and poster presentations from Bionano and a panel discussion featuring esteemed researchers from across the cancer genomics landscape.

HebeCell Corp (HebeCell) and Logomix Inc (Logomix) today announced a strategic partnership to research and develop gene-edited NK cells and discover genetic modifications that can create next generation designer NK cells.

Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2024, ended June 30, 2023.

Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2023.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced financial results for the second quarter ended June 30, 2023.

Sunshine Biopharma Inc., a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals announced that it has filed its quarterly report for the 2023 second quarter.

Zumutor Biologics Inc “Zumutor”, a Boston based biopharmaceutical company focused on developing unique novel therapeutics in immuno-oncology (I-O) today announces that the US Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for the novel drug ZM008 to initiate a Phase 1, first-in-human, clinical study for the treatment of multiple solid cancers.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update.

BillionToOne, experts in fetal DNA quantification, announced that Scientific Reports published a study1 of the UNITY Fetal Antigen Noninvasive Prenatal Test.